Back to top

Assertio Therapeutics: Buy Rating Affirmed Amid Strong ROLVEDON Growth and Positive Financial Outlook

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Assertio Therapeutics (ASRT – Research Report) and keeping the price target a...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Assertio Holdings, Inc. (ASRT)